Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167144993> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W3167144993 endingPage "4097" @default.
- W3167144993 startingPage "4097" @default.
- W3167144993 abstract "4097 Background: In FOENIX-CCA2 (NCT02052778), a pivotal phase 2 study among iCCA patients (pts) with FGFR2 fusions/rearrangements, the highly selective, irreversible FGFR1–4 inhibitor futibatinib demonstrated a confirmed objective response rate of 41.7%, with a 9.7-month median duration of response. Adverse events were manageable with dosing modifications that did not adversely impact on response. We report outcomes for the preplanned analysis of Patient-Reported Outcomes (PROs) during futibatinib treatment as a secondary objective of FOENIX-CCA2. Methods: Pts enrolled in FOENIX-CCA2 had locally advanced/metastatic unresectable iCCA with FGFR2 fusions/rearrangements, ≥1 prior line of therapy (including gemcitabine/cisplatin) and ECOG PS 0-1. Pts received oral futibatinib 20 mg continuous QD dosing per 21-day cycle. PRO measures included EORTC-QLQ-C30 (1 global health, 5 functional, 9 symptom scales), EQ-5D-3L, and EQ visual analogue scale (VAS). PROs were collected at screening, cycles 2 and 4, every 3 cycles thereafter, and end of treatment. PRO data were evaluated up to cycle 13, the last visit before data were missing for >50% of the PRO population (PRO primary assessment time point). Results: 92/103 (89.3%) pts enrolled had PRO completion data at baseline and a minimum of 1 follow-up assessment (median age 58 y, 56.5% female), with 48 pts having PRO data at cycle 13. At baseline, mean (SD) EORTC QLQ-C30 global health status score was 70.1 (19.4) and EQ VAS score 71.7 (20.3). Mean EORTC QLQ-C30 global health status scores were maintained from baseline to cycle 13, corresponding to 9.0 months on treatment, with no clinically meaningful (≥10-point) changes in individual functional measures (Table). EORTC QLQ-C30 scores across individual symptom measures were also stable from baseline through cycle 13; only constipation showed an average of 10.0-point worsening at only cycle 4. Mean EQ VAS scores were sustained from baseline to cycle 13 (mean change ranging -1.8 to +4.8 across cycles), with values maintained within the population norm range from across 20 countries. Conclusions: Quality of life data from the phase 2 FOENIX-CCA2 trial show that physical, cognitive and emotional functioning, and overall health status were maintained among pts with advanced iCCA receiving futibatinib. Clinical trial information: NCT02052778. [Table: see text]" @default.
- W3167144993 created "2021-06-22" @default.
- W3167144993 creator A5006585898 @default.
- W3167144993 creator A5009244604 @default.
- W3167144993 creator A5038907472 @default.
- W3167144993 creator A5056197140 @default.
- W3167144993 creator A5058709133 @default.
- W3167144993 creator A5076426660 @default.
- W3167144993 creator A5077826150 @default.
- W3167144993 creator A5081369942 @default.
- W3167144993 creator A5083898918 @default.
- W3167144993 creator A5085030098 @default.
- W3167144993 creator A5086593040 @default.
- W3167144993 date "2021-05-20" @default.
- W3167144993 modified "2023-10-01" @default.
- W3167144993 title "FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with <i>FGFR2</i> fusions/rearrangements." @default.
- W3167144993 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4097" @default.
- W3167144993 hasPublicationYear "2021" @default.
- W3167144993 type Work @default.
- W3167144993 sameAs 3167144993 @default.
- W3167144993 citedByCount "4" @default.
- W3167144993 countsByYear W31671449932021 @default.
- W3167144993 countsByYear W31671449932022 @default.
- W3167144993 crossrefType "journal-article" @default.
- W3167144993 hasAuthorship W3167144993A5006585898 @default.
- W3167144993 hasAuthorship W3167144993A5009244604 @default.
- W3167144993 hasAuthorship W3167144993A5038907472 @default.
- W3167144993 hasAuthorship W3167144993A5056197140 @default.
- W3167144993 hasAuthorship W3167144993A5058709133 @default.
- W3167144993 hasAuthorship W3167144993A5076426660 @default.
- W3167144993 hasAuthorship W3167144993A5077826150 @default.
- W3167144993 hasAuthorship W3167144993A5081369942 @default.
- W3167144993 hasAuthorship W3167144993A5083898918 @default.
- W3167144993 hasAuthorship W3167144993A5085030098 @default.
- W3167144993 hasAuthorship W3167144993A5086593040 @default.
- W3167144993 hasConcept C121608353 @default.
- W3167144993 hasConcept C126322002 @default.
- W3167144993 hasConcept C141071460 @default.
- W3167144993 hasConcept C14184104 @default.
- W3167144993 hasConcept C143998085 @default.
- W3167144993 hasConcept C159110408 @default.
- W3167144993 hasConcept C197934379 @default.
- W3167144993 hasConcept C203092338 @default.
- W3167144993 hasConcept C2777288759 @default.
- W3167144993 hasConcept C2779951463 @default.
- W3167144993 hasConcept C2780258809 @default.
- W3167144993 hasConcept C2908647359 @default.
- W3167144993 hasConcept C2909135397 @default.
- W3167144993 hasConcept C535046627 @default.
- W3167144993 hasConcept C71924100 @default.
- W3167144993 hasConcept C90924648 @default.
- W3167144993 hasConcept C99454951 @default.
- W3167144993 hasConceptScore W3167144993C121608353 @default.
- W3167144993 hasConceptScore W3167144993C126322002 @default.
- W3167144993 hasConceptScore W3167144993C141071460 @default.
- W3167144993 hasConceptScore W3167144993C14184104 @default.
- W3167144993 hasConceptScore W3167144993C143998085 @default.
- W3167144993 hasConceptScore W3167144993C159110408 @default.
- W3167144993 hasConceptScore W3167144993C197934379 @default.
- W3167144993 hasConceptScore W3167144993C203092338 @default.
- W3167144993 hasConceptScore W3167144993C2777288759 @default.
- W3167144993 hasConceptScore W3167144993C2779951463 @default.
- W3167144993 hasConceptScore W3167144993C2780258809 @default.
- W3167144993 hasConceptScore W3167144993C2908647359 @default.
- W3167144993 hasConceptScore W3167144993C2909135397 @default.
- W3167144993 hasConceptScore W3167144993C535046627 @default.
- W3167144993 hasConceptScore W3167144993C71924100 @default.
- W3167144993 hasConceptScore W3167144993C90924648 @default.
- W3167144993 hasConceptScore W3167144993C99454951 @default.
- W3167144993 hasIssue "15_suppl" @default.
- W3167144993 hasLocation W31671449931 @default.
- W3167144993 hasOpenAccess W3167144993 @default.
- W3167144993 hasPrimaryLocation W31671449931 @default.
- W3167144993 hasRelatedWork W1966541007 @default.
- W3167144993 hasRelatedWork W1997961771 @default.
- W3167144993 hasRelatedWork W2002483815 @default.
- W3167144993 hasRelatedWork W2087566648 @default.
- W3167144993 hasRelatedWork W2144025124 @default.
- W3167144993 hasRelatedWork W2147938475 @default.
- W3167144993 hasRelatedWork W2183237771 @default.
- W3167144993 hasRelatedWork W2403481407 @default.
- W3167144993 hasRelatedWork W3176730799 @default.
- W3167144993 hasRelatedWork W4306253774 @default.
- W3167144993 hasVolume "39" @default.
- W3167144993 isParatext "false" @default.
- W3167144993 isRetracted "false" @default.
- W3167144993 magId "3167144993" @default.
- W3167144993 workType "article" @default.